Detection and treatment of autoimmune disorders
AssigneeSeattle Children's Hospital
InventorsNeelufar Mozaffarian, Anne M. Stevens
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods of treatment of autoimmune diseases such as systemic lupus erythematosus (SLE) as well as clinical assays for detection of autoimmune disease activity in patients utilizing a PD1 ligand.
Claims29
1-9. (canceled)
A method of distinguishing between the presence of systemic lupus erythematosus (SLE) and a bacterial or viral infection in a human subject suspected of having or at risk of having SLE or a bacterial or viral infection comprising:
- determining the amount of circulating PD-L1 in a blood sample obtained from the human subject by contacting the blood sample with a detectably labeled antibody specific for PD-L1;
- wherein a circulating PD-L1 amount that is lower than a control value is indicative of SLE and a circulating PD-L1 amount that is higher than the control value is indicative of a bacterial or viral infection.
(canceled)
A method of distinguishing between an active autoimmune disease and an autoimmune disease in remission in a human subject comprising:
- determining the amount of circulating PD-L1 in a blood sample obtained from the human subject by contacting the blood sample with a detectably labeled antibody specific for PD-L1;
- and
- wherein a circulating PD-L1 amount that is lower than a control value is indicative of active autoimmune disease and a circulating PD-L1 amount that is about equal to the control value is indicative of remission.
(canceled)
21-39. (canceled)
Dependencies are inferred from the claim text.